1 document found, page 1 of 1

Sort by Issue Date
go first page go previous page
go to page: 1
go next page go last page
rss feed search results

AT LAST! It was not a progression!

Paulinetti Camara, Raquel; Lopes, Kelly; Barbosa, Miguel; Sucena, Inês; Simão, Carla; Mota, Paulo; Matias, Dina; Sequeira, Telma; Almodovar, Teresa

Introduction: Nivolumab is approved in Portugal for non-small cell metastatic lung cancer, as one of the indications, after progressing on chemotherapy. As an immune checkpoint inhibitor (ICI) immune-related adverse events (irAE) are possible reactions. Case report: A 64-year-old man with stage III lung adenocarcinoma who progressed after chemoradiotherapy and first line metastatic chemotherapy started nivoluma...

Date: 2024   |   Origin: THORAC (Thoracic Cancer Journal)
More info.
go first page go previous page
go to page: 1
go next page go last page
rss feed search results

1 Results

Queried text

Refine Results

Author










Date


Document Type


Access rights


Resource


Subject